Oxford Biomedica Share Discussion Threads

[harry s truman] 05/7/2022 09:26

And (just to chip in here) seems to be more proof that when big pharma decide that they are going to be active in a particular area then they just go shopping and save the lost time / risk of developing something themselves.

Did anybody see the stories yesterday in the news about the lady with triple negative breast cancer which had spread? Zero options with best current treatments and so she enrolled on a trial and is now cancer free.

With the bowel cancer trial news the other day then two examples of difficult to treat hard tumour situations and fixed in trials?

It didn't say which trial or which trial drug in the stories I read, but regardless of which company then what a fantastic achievement. For decades people have been working towards smart / targeted medicines and maybe we are finally just about there.

[marcusl2] 05/7/2022 09:14

PH,
TNB-486 is a fully human bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells. Scancell are doing the same with their Glymabs targeting CD3. It`s a hot area, big money deals.

[pharmaboy3] 05/7/2022 07:06

AZN moving into T cell arenaAstraZeneca PLC - AstraZeneca to acquire TeneoTwo and T cell engager #AZN @AstraZeneca HTTps://www.voxmarkets.co.uk/rns/announcement/e243166a-8df0-47e2-9fd5-ae45a4b9ebcd #voxmarkets

[dominiccummings] 04/7/2022 16:59

Still bodging on bodger.

[harry s truman] 04/7/2022 14:58

Today of course the end of a big holiday weekend and thus the US market closed. 19k shares traded so far today - which is almost nothing for us.

[badger60] 04/7/2022 13:57

What are you drivelling on about Cummings?

[dominiccummings] 04/7/2022 12:51

Working hard for your revenge bodger. But you overestimate just how much these posts count in the real world.

[badger60] 04/7/2022 11:30

Without any really good news the share price will be breaking 4 quid sooner rather than later. The inept OXB management have put the kiss of death on this company and doubtless will have to raise more equity finance. I'm sure that long suffering shareholders will be overjoyed to subscribe for yet more new shares........

[badger60] 04/7/2022 09:04

Fwiw looking at the one year period from end March 2022 to end March 2023, group cash burn is circa 200 Mio (circa 50 Mio UK and circa 80 Mio US) quid, and 70 Mio quid for the loan repayment ...., .....OXB group are burning 3.85 Mio quid a week!!!
They'll be lucky to make 60 mio in revenue in the year.......which includes the 30 Mio from AZN which is already known as is the 19 Mio Homology gift repayment back to OXB.

[blinddarts] 03/7/2022 22:51

This time last year Rodney.......:-)

[badger60] 02/7/2022 01:36

Not me Harry....looks more like shatter, post1..14/6 created this account. Very useful though.
I agree with your "sigh of relief" post which realistically evaluates the AZN RNS. The share price action certainly recognises its limited value.
Unfortunately I think that your other dreams of lucrative contracts from elsewhere will be a steep hill to climb, especially given the ineptitude of OXB's current management......and their Homology investment fiasco.

[dominiccummings] 01/7/2022 21:45

It was my understanding that we were given a reasonable margin given the volume by AZ. It was AZ that provided the finished vaccine at cost, and all they get for it was a bloody nose from Pfizer, the US Drug agency and the EU. Oh, and a knighthood for Sir Pascal Soriot.

[gareth jones] 01/7/2022 17:50

It would be nice to know if the contract it now at commercial rates rather than "mates rates" particularly since WHO said Covid-19 is now an inconvenience rather than a killer disease for many people. I don't think WHO have yet formally declared the pandemic over.

[harry s truman] 01/7/2022 15:26

This is the first time I've ever read that Serum wanted to use OxBox for Covid vaccines. OXB have never said that.



Oxford Biomedica signs up for 3 more years of making AstraZeneca COVID shots⁠—on an 'as needed basis'
By Kevin DunleavyJul 1, 2022 02:50pm

There was a time—not so long ago—when COVID-19 vaccine manufacturers couldn’t produce doses fast enough.

But that was then, and this is now: Friday, when Oxford Biomedica revealed an extension of its contract with AstraZeneca through 2025, the deal was to make shots on an “as needed basis,” the company said.

This comes just nine months after Oxford announced a 50 million pound sterling ($68 million) investment from the over-strapped Serum Institute of India to increase its ability to manufacture COVID vaccines for AZ at its Oxbox facility.

At that time, three of Oxford's four production suites were engaged in making shots for AZ. As part of the investment, Oxford planned to bring on 120 additional employees.

Since signing on to make AZ shots in September of 2020, Oxford has produced more than 100 million doses. It will continue to make vaccines through the fourth quarter of 2022 and will realize revenue of 30 million pounds ($36 million) from those efforts this year, the company said.

But now, Oxford’s attention has returned to its primary mission to support the development and production of cell and gene therapies.

Producing the COVID vaccines has demonstrated the company’s “ability to expand the scope of our innovative process development services and deliver high-performing manufacturing solutions beyond lentiviral vectors,” Oxford Chairman and interim CEO Roch Doliveux said in a statement. “We look forward to continuing to work closely with AstraZeneca and execute on our strategy to become a global leader across all viral vectors.”

In February of this year, Oxford said it had raised 39.4 million pounds ($53.3 million) in a share placing to help fund an 80% buy into U.S. viral vector manufacturer Homology Medicines.

A month later, the company launched Boston-based Oxford Biomedica Solutions, with a “plug and play” platform it said.

[harry s truman] 01/7/2022 15:20

FT

Oxford BioMedica extends Covid vaccine deal with AstraZeneca
New three-year contract in place if UK drugmaker continues to manufacture the jab



Oxford BioMedica has extended its partnership with AstraZeneca, agreeing a new three-year contract to manufacture Covid-19 vaccines if the UK drugmaker presses on with mass production of the jab.

The specialist pharmaceutical manufacturer, which also makes cell and gene therapies, will make its Oxbox facility available on an “as needed” basis to AstraZeneca after 2022. The original contract signed in September 2020 is expected to complete in the last quarter of this year, with Oxford BioMedica recognising roughly £30mn from AstraZeneca this financial year.

Roch Doliveux, chair and interim chief executive of Oxford BioMedica, said he was proud of the work the company had done to deliver more than 100mn doses of the Covid vaccine.

“While contributing to the efforts to fight the pandemic, this has also demonstrated Oxford BioMedica’s ability to expand the scope of our innovative process development services,” he said, adding that it had helped the company’s strategy to expand into producing other delivery mechanisms for vaccines and drugs.

Before AstraZeneca partnered with Oxford university to develop its Covid vaccine, the pharmaceutical company did not have a significant vaccine business. Last year, it formed a new unit including the Covid jab, alongside its nasal flu vaccine and infectious disease treatments, but has not announced a plan to invest in vaccines in the long term.

AstraZeneca is signing for-profit contracts in middle-income countries for the vaccine, but Europe and the UK have so far opted to fuel their booster campaigns with mRNA jabs developed by BioNTech/Pfizer and Moderna.

The US has not yet approved the AstraZeneca vaccine and the company’s head of research and development told the Financial Times in March that it would not necessarily persist in applying for the approval in the world’s largest pharmaceutical market if it finds it is “banging its head against a brick wall indefinitely”.

In the initial trials, the vaccine was less effective than the mRNA rivals, although it offers strong protection against severe disease and death. Some countries abandoned it after it was linked with a very rare blood clotting side effect, and others were disappointed by manufacturing delays at some contractors.

Shares in Oxford BioMedica rose 3.6 per cent to 470.5p in early morning trading in London on Friday. The stock has fallen 62 per cent so far this year, amid a wider sell-off in the biotech market, as investors anticipated a decline or end to the Covid vaccine revenues.

[harry s truman] 01/7/2022 15:17

The Times (see last paragraph from Peel Hunt)



Oxford Biomedica signs new 3-year deal with AstraZeneca
Alex Ralph
Friday July 01 2022, 9.00am BST, The Times

One of the key British manufacturers behind the Oxford University-AstraZeneca Covid-19 vaccine has signed a new three-year agreement with the drugs company.

Oxford Biomedica, whose commitments under a previous deal for AstraZeneca’s vaccine will end at the end of this year, said the new deal should “facilitate potential future manufacturing opportunities” for the vaccine.

The company also said it expected to record about £30 million in revenue from the existing agreement with AstraZeneca during this financial year, higher than City forecasts.

Shares in Oxford Biomedica traded at a high of more than £16 in September last year but fell almost to £4 last month. They traded up 1.9 per cent, or 8½p, to 462½p this morning.

The active ingredient of the vaccine is being made at Oxford Biomedica’s £20 million, 84,000 sq ft facility called Oxbox on the site of a former Royal Mail sorting office on the city’s business park. The company, a specialist contract manufacturer for cell and gene therapies, was spun out of Oxford University in 1996 and initially listed on London’s junior AIM market.

The contract has boosted Oxford Biomedica’s finances, profile and it has since been expanding in the vector market in the United States.

The company was part of a consortium of manufacturers assembled by AstraZeneca, the Cambridge-based drugs group that licensed the vaccine from Oxford University, during the height of the pandemic in 2020.

It struck an initial three-year supply and development agreement in September 2020 and has successfully manufactured more than 100 million doses of the vaccine and generated revenues of more than £100 million by the end of last year, contributing to “significant growth” in revenues and earnings last year.

Total revenues increased by 63 per cent to £142.8 million and underlying operating earnings rose to £35.9 million, up £28.5 million from the previous year.

The City has long been awaiting news of an extension to a deal and shares weakened in April after the company revealed that manufacturing had been paused.

Roch Doliveux, Oxford Biomedica’s chairman and interim chief executive, had moved to reassure investors in April that it expected “continued activity” with AstraZeneca but “not at the same level” as last year when it was operating “24/7”.

Sir Pascal Soriot, the chief executive of AstraZeneca, had also said in April that the Oxford vaccine still had an important global role, despite the company expecting a decline in sales and worldwide “oversupply” as the pandemic waned. Soriot, 63, had said at the time that it was difficult to predict demand for Covid jabs as “we are no longer in a period of scarcity”.

Analysts at Peel Hunt said this morning that the £30 million revenues from the existing contract this year was an “uplift to our current 2022 expectations of £14.2 million and should see about £6 million benefit to 2022 gross profit”. They added: “We do not yet assume any further revenues for 2023-24 but are encouraged by the length of the new agreement.”

[harry s truman] 01/7/2022 15:13

toottootroot
Member since: 01 Jul 2022
Number of posts: 1

Always a chortle when you think that someone has gone to the trouble of creating a new account. What's that old one about a badger not being able to...?

[badger60] 01/7/2022 13:46

I can just see the AZN order in the post........

Dear OXB could you please supply 460 non blood clot forming Covid Vax doses......1 for each penny of your share price.....kind regards...etc ..

[badger60] 01/7/2022 13:24

Sp rise after RNS....ho ho ho ho!!
Not much in this for OXB from AZN....if anything. So it will be back to the begging bowl before too long........130 Mio quid in new OXB shares have already been issued in the last 10 months........
Existing OXB shareholders just love yet another new issue.....at this rate it will be share consolidation time again.......

[badger60] 01/7/2022 13:16

Read it again cretin. I didn't say AZN was a US company, but falls into the big pharma category.......which of course is global and not just confined to the US.....you stupid boy!!

[dominiccummings] 01/7/2022 12:35

Well, that carefully worded RNS, although very positive for OXB's current financial performance, seems to have been swallowed by the market 'without touching the sides'!